Mai Yoshida

Mai Yoshida

Auto-generated profile, based on publicly available information

Mai Yoshida

Department of Dermatology, Nippon Medical School, Bunkyo City 113-8602, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MYMai Yoshida
Mai Yoshida
YFYoko Funasaka
Yoko Funasaka
HSHidehisa Saeki
Hidehisa Saeki
MYMasami Yamamoto
Masami Yamamoto
Naoko KandaNaoko Kanda
Naoko Kanda
Psoriasis is a chronic skin disease with interleukin (IL)-17-dominated inflammation and hyperproliferation of epidermis. Dietary fiber is fermented by the gut microbiome into short-chain fatty acids (SCFAs) that manifest anti-inflammatory effects. We examined if feeding with an inulin-enriched high-fiber diet (HFD) might improve topical imiquimod-induced psoriasis-like dermatitis in mice. HFD reduced thickening and total severity scores of imiquimod-induced dermatitis and reduced epidermal thickness, inflammatory infiltrates, including Ly6G+ neutrophils, and epidermal Ki67+ proliferating cells. HFD reduced mRNA levels of IL-17A, IL-17F, IL-22, IL-1β, tumor necrosis factor (TNF)-α, CXCL1, CXCL2, and keratin 16 and increased those of transforming growth factor (TGF)-β1 and cyclin-dependent kinase inhibitor 1A in imiquimod-induced dermatitis. In 16S rRNA sequencing of the gut microbiome, imiquimod increased relative abundance of phylum Firmicutes, while HFD increased that of phylum Bacteroidota and genus Bacteroides. HFD increased serum and fecal concentrations of SCFA propionate. Oral propionate reduced inflammatory infiltrates and epidermal Ki67+ cells and reduced mRNA levels of IL-17A, IL-17F, IL-17C, IL-22, IL-1β, IL-6, TNF-α, CXCL1, CCL20 and increased those of TGF-β1and IL-10 in imiquimod-indued dermatitis. Dietary inulin supplementation improves imiquimod-induced psoriasis-like dermatitis partially via propionate, and may be a promising adjunctive therapy for psoriasis.

18 April 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
THTeppei Hagino
Teppei Hagino
RHRisa Hamada
Risa Hamada
MYMai Yoshida
Mai Yoshida
HSHidehisa Saeki
Hidehisa Saeki
EFEita Fujimoto
Eita Fujimoto
Naoko KandaNaoko Kanda
Naoko Kanda
Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash and pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether the early reduction in rash or pruritus at week 12 of upadacitinib treatment could be maintained at later treatment stages. This retrospective study involved 227 and 73 patients with moderate-to-severe AD treated with 15 and 30 mg upadacitinib daily, respectively. The eczema area and severity index (EASI) scores, peak pruritus numerical rating scale (PP-NRS), and investigator’s global assessment (IGA) were analyzed. At week 12, patients were divided into achievers and non-achievers of EASI 75, 90, 100, absolute EASI ≤ 2, IGA0/1, PP-NRS4, or absolute PP-NRS ≤ 1. Achievement rates for each endpoint were assessed at later time points (weeks 24, 36, and 48) in both groups. Week 12 achievers largely maintained their endpoint achievements until week 48, regardless of dosage (15 mg or 30 mg). Week 12 non-achievers saw an increasing achievement rate of EASI 75 until week 48. The initial reduction in rash and pruritus at week 12 persisted until week 48 with upadacitinib treatment, suggesting potential benefits for patients requiring prolonged treatment despite not achieving EASI 75 at week 12.

27 February 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TSTeppei Sugano
Teppei Sugano
MSMasahiro Seike
Masahiro Seike
YFYoko Funasaka
Yoko Funasaka
MYMai Yoshida
Mai Yoshida
RTRyoko Takayama
Ryoko Takayama
AGAkihiko Gemma
Akihiko Gemma
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointestinal, endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic cutaneous disorder with a reactive inflammatory component, which often occurs in patients with rheumatoid arthritis. Case presentation We present a 67-year-old man with lung adenocarcinoma who developed ILH associated with pembrolizumab treatment. He was treated with palliative thoracic radiotherapy for superior vena cava syndrome. Subsequently, he received four cycles of pembrolizumab. Approximately 2.5 months after the initiation of pembrolizumab, he developed erythema on the trunk of his body. Based on findings of skin biopsies, he was diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor necrosis factor-α was observed during pembrolizumab therapy. Conclusions This is the first report of ILH induced by pembrolizumab in a patient with lung adenocarcinoma.

Verified
Journal Article
Open access
PDF file
MYMai Yoshida
Mai Yoshida
THTeppei Hagino
Teppei Hagino
MYManami Yoneyama
Manami Yoneyama
HSHidehisa Saeki
Hidehisa Saeki
Naoko KandaNaoko Kanda
Naoko Kanda
Psoriasis is a chronic skin disease manifesting scaly, indurated erythema and an enhanced interleukin (IL)-23/IL-17 immune axis. A high-salt diet (HSD) is known to promote several autoimmune or autoinflammatory diseases. We examined whether an HSD might exacerbate topical imiquimod (IMQ)-induced psoriasis-like dermatitis in mice. Balb/c female mice were fed a normal diet (ND, 0.2% NaCl) or an HSD (4.2% NaCl) for 3 weeks, and 25 mg IMQ was applied to shaved back skin for 5 consecutive days. Compared to ND, the HSD exacerbated IMQ-induced psoriasiform dermatitis with increased scale, skin thickness, and total scores, and histologically enhanced epidermal thickening, hyperkeratosis, and dermal inflammatory infiltrates, including Ly6G+ neutrophils and CD3+ T cells. HSD increased mRNA levels of Il17a, Il22, Tnfa, Il1b, Il23a, Il23r, Cxcl1, Ccl20, Krt16, and Ccnd1 in IMQ-induced dermatitis. HSD increased the immunostaining areas of whole and Ser 422-phosphorylated forms of serum- and glucocorticoid-inducible kinase 1 (SGK1) in epidermal keratinocytes and dermal-infiltrating cells in IMQ-induced dermatitis. Intraperitoneal SGK1 inhibitor EMD638683 reversed the above effects of HSD in exacerbating IMQ-induced dermatitis. Our present results indicate that HSD may exacerbate murine IMQ-induced psoriasis-like dermatitis at least partially through the activation of SGK1.